Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12215466 | 0.88 | CYP2C9 (0.44) | CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL2628952 | 0.88 | CYP2C9 (0.47) | CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL7063069 | 0.88 | CYP2C9 (0.41) | CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6 | |
| Potassium Ion SCHEMBL1763584 | 0.87 | CYP2C9 (0.43) | CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL13119403 | 0.85 | CYP2C9 (0.57) | CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL13899210 | 0.85 | CYP2C9 (0.44) | CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL2628870 | 0.85 | NR4A2 (0.36) | CYP2C9CYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL9942576 | 0.85 | NR4A2 (0.35) | CYP2C9NR4A2 | |
| SCHEMBL3933553 | 0.84 | CYP2C9 (0.43) | CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL1763549 | 0.84 | NR4A2 (0.35) | CYP2C9NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190328900-A1 | ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-9920073-B2 | Compositions useful for inhibiting HIV-1 infection and methods using same | DREXEL UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20150329543-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| US-20150259342-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20090306095-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-7501420-B2 | Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501420-B2 | Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-7354924-B2 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354924-B2 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | CYP2C9 905/4885CYP3A4 121/4885CYP1A2 175/4885 |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CYP2C9 1182/4885CYP3A4 162/4885CYP1A2 175/4885 |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | CCL5, CCR5, CXCL10 | CYP2C9 4831/4885CYP3A4 4235/4885CYP1A2 4318/4885 |
| US-20090306095-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CYP2C9 2812/4885CYP3A4 494/4885CYP1A2 916/4885 |
| US-20150329543-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | CYP2C9 905/4885CYP3A4 121/4885CYP1A2 175/4885 |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CYP2C9 2812/4885CYP3A4 494/4885CYP1A2 916/4885 |
| US-20150259342-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CYP2C9 1182/4885CYP3A4 162/4885CYP1A2 175/4885 |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1411/4885CYP3A4 175/4885CYP1A2 363/4885 |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | EIF2AK2, DCK, MAVS | CYP2C9 3136/4885CYP3A4 1204/4885CYP1A2 2178/4885 |
| US-20190328900-A1 | ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME | CD4, ABCB1, FCGR3B | CYP2C9 1024/4885CYP3A4 846/4885CYP1A2 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.